Contentious Pricing Mechanism Adopted In Canada But Only For ‘A Brief Period’

 
• By Neena Brizmohun

Drug companies are unhappy about a new median price test and the exclusion of the Consumer Price Index in the amended interim guidance from the Patented Medicine Prices Review Board

The PMPRB's mandate is to ensure that medicine prices are not excessive in Canada • Source: Shutterstock

More from Canada

More from North America